Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models  by Mastan, S.K. & Kumar, K. Eswar
International Journal of Diabetes Mellitus 2 (2010) 56–60Contents lists available at ScienceDirect
International Journal of Diabetes Mellitus
journal homepage: ees .e lsevier .com/ locate/ i jdmBrief Communication
Inﬂuence of atazanavir on the pharmacodynamics and pharmacokinetics
of gliclazide in animal models
S.K. Mastan a,*, K. Eswar Kumar b
aResearch Scholar, Jawaharlal Nehru Technological University, Hyderabad 500 072, Andhra Pradesh, India
b Pharmacology Division, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530 003, Andhra Pradesh, IndiaOpen access under CC BY-NC-ND license.a r t i c l e i n f o
Article history:
Received 20 July 2009
Accepted 5 October 2009
Keywords:
Gliclazide
Atazanavir
Diabetes
HIV infection
Hypoglycemia
Pharmacokinetics1877-5934  2009 International Journal of Diabetes M
doi:10.1016/j.ijdm.2009.10.001
* Corresponding author. Tel.: +91 891 2733737; fax
E-mail addresses: shkmastan@gmail.com (S.K. Ma
(K.E. Kumar).a b s t r a c t
Background: The objective of this study was to investigate the effect of atazanavir on the pharmacody-
namics and pharmacokinetics of gliclazide in rats (normal and diabetic) and rabbits to evaluate the safety
and effectiveness of the combination.
Methods: Blood samples were analysed for blood glucose by GOD/POD method, serum gliclazide levels by
HPLC method and insulin by Radio Immuno Assay method.
Results: In combination, atazanavir signiﬁcantly enhanced the pharmacodynamic activity and altered the
pharmacokinetic parameters of gliclazide in animal models.
Conclusions: The interaction between atazanavir and gliclazide appears to be pharmacokinetic interac-
tion at metabolic level in animal models.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.1. Introduction
The study of mechanisms of drug interaction is of much value in
selecting drug concentrations to provide rational therapy. Drug
interaction studies assume much importance, especially for drugs
that have a narrow margin of safety, and where the drugs are used
for a prolonged period of time. Diabetes mellitus is one such met-
abolic disorder that needs treatment for prolonged periods, and
maintenance of normal blood glucose level is very important in
this condition, since both hyperglycemia, as well as hypoglycemia,
is unwanted phenomenon [1].
Diabetes mellitus is a chronic metabolic disorder characterized
by elevated blood glucose levels and disturbances in carbohydrate,
fat and protein metabolism, and an increased risk of complications
from vascular disease. Diabetes may be due to a decrease in the
synthesis of insulin (type-1) or a decrease in the secretion of insu-
lin (type-2) from the b-cells of islets of Langerhans of the pancreas.
There are an estimated 143 million people world wide sufferings
from diabetes [2] and the number may well double by the year
2030 [3]. In India, the prevalence rate of diabetes is estimated to
be 1–5%.
Insulin resistance, impaired glucose tolerance and type-2 diabe-
tes are conditions that are increasingly described in HIV-1 infectedellitus. Published by Elsevier Ltd.
: +91 891 2525611.
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Osubjects receiving highly active antiretroviral therapy (HAART),
especially with protease inhibitors (PIs) [4,5]. Atazanavir is a com-
monly prescribed protease inhibitor, due to its once-daily dosing
regimen, favorable metabolic proﬁle and low frequency of adverse
effects [6]. However, its effect on oral antidiabetic therapy is not
known.
Oral hypoglycemic agents are used in the treatment of type-2
diabetes, among which gliclazide, a second generation sulphonylu-
rea derivative, is preferred in therapy because of its selective inhib-
itory activity towards pancreatic K+ ATP channels [7], antioxidant
property [8], low incidence of producing severe hypoglycemia [9]
and other haemobiological effects. Gliclazide is known to act
mainly by releasing insulin by blocking K+ channels in the pancre-
atic b-cells [10].
Atazanavir is a substrate and potent inhibitor of the cytochrome
P450 (CYP) system, in particular CYP3A4 and CYP2C9 and affect the
metabolism of several drugs [11]. Because atazanavir can inhibit
CYP3A4 and CYP2C9-mediated drug metabolism and gliclazide is
reported to be metabolized by CYP2C9 primarily and partly by
CYP3A4 [10,12], it is important to study the possible effects of ataz-
anavir on the pharmacokinetics and pharmacodynamics of glicla-
zide. However, there seem to be no published studies on the
effects of enzyme inhibition on the pharmacokinetics of gliclazide.
Since there is every possibility for the combined use of glicla-
zide and atazanavir in chronic diabetics with associated HIV infec-
tion, the study is planned to investigate the effect of atazanavir on
the activity of gliclazide in normal and diabetic rats, to evaluate thepen access under CC BY-NC-ND license.
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planned to ﬁnd the pharmacodynamics and pharmacokinetics of
gliclazide in the presence of atazanavir in rabbits, to evaluate the
mechanisms of interaction if they occur.2. Material and methods
2.1. Drugs and chemicals
Gliclazide and atazanavir are gift samples from Micro Labs
(Bangalore, India) and Aurobindo Pharma Ltd. (Hyderabad, India),
respectively. Alloxan monohydrate was purchased from LOBA Che-
mie (Mumbai, India). Glucose kits (span diagnostics) were pur-
chased from a local pharmacy. Acetonitrile (HPLC grade) was
obtained from Qualigens chemicals, Mumbai, India. Orthophos-
phoric acid (AR grade) and dichloromethane (AR grade) were pur-
chased from SD Fine Chemicals, Mumbai, India and Loba Chemie
Pvt. Ltd., Mumbai, India, respectively. All other reagents used were
of an analytical grade.2.2. Animals
Albino rats of either sex, 6–7 weeks of age, weighing between
250 to 320 g, and normal albino rabbits of either sex of 3 months
of age, weighing between 1.35 to 1.75 Kg, were used in the study.
They were procured from the National Institute of Nutrition,
Hyderabad, India. They were maintained under standard labora-
tory conditions at an ambient temperature of 25 ± 2 C and
50 ± 15% relative humidity, with a 12-h light/12-h dark cycle. Ani-
mals were fed with a commercial pellet diet (Rayan’s Biotechnolo-
gies Pvt. Ltd., Hyderabad, India) and water ad libitum. They were
fasted for 18 h prior to the experiment, and during the experiment,
the food and water were withdrawn. The animal experiments were
performed after prior approval of the study protocol by the Institu-
tional Animal Ethics Committee and by the Government regulatory
body for animal research. (Reg. No. 516/01/A/CPCSEA). The study
was conducted in accordance with the guidelines provided by
the Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA).2.3. Selection of doses and preparation of oral test solution/suspension
In clinical practice, atazanavir and gliclazide in a therapeutic
dose will be administered orally as antiretroviral and antidiabetic
therapy, respectively. Human oral therapeutic doses of the respec-
tive drugs were extrapolated to rat/rabbit based on body surface
area [13]. But the dose of gliclazide for rat experiments was se-
lected as 2 mg/kg bd. wt. based on the inﬂuence of dose effect-rela-
tionship of gliclazide on blood glucose in normal rats. Atazanavir
was suspended in 2% CMC-Na for oral administration [14]. Glicla-
zide solution was prepared by dissolving it in a few drops of
0.1 N NaOH then made up to the volume with distilled water. All
the drugs were administered to the respective groups by oral
gavage.2.4. Pharmacodynamic interaction study in normal and diabetic rats
A group of six normal rats was administered with 2 mg/
kg bd. wt. of gliclazide, orally. The same group was administered
with atazanavir 36 mg/kg bd. wt., orally and the combination of
atazanavir and gliclazide. One week washout period was main-
tained between treatments. After this single dose interaction
study, the same group was continued with the daily treatment of
interacting drug (atazanavir) for the next 8 days with regular feed-ing. Later after 18 h fasting, they were again given the combined
treatment on the 9th day.
The same treatment (single dose followed by multiple dose
interaction study) was repeated in a group of six alloxan-induced
diabetic rats. Diabetes was induced in rats by the administration
of alloxan monohydrate in two doses, i.e. 100 mg and 50 mg/
kg bd. wt. intraperitoneally for two consecutive days [15]. After
72 h, samples were collected from rats by orbital puncture of all
surviving rats, and the serum was analysed for glucose levels. Rats
with blood glucose levels of 200 mg/dl and above were considered
as diabetic and selected for the study.
Blood samples were withdrawn from retro orbital plexus [16] of
each rat at 0, 1, 2, 3, 4, 6, 8 and 12 h. These blood samples were
analysed for blood glucose by GOD/POD method [17] using com-
mercial glucose kits.2.5. Pharmacodynamic and pharmacokinetic interaction study in
rabbits
A group of six rabbits was administered with 5.6 mg/
1.5 kg bd. wt. of gliclazide, orally. The same group was adminis-
tered with atazanavir 28 mg/1.5 kg bd. wt., orally and the combi-
nation of atazanavir and gliclazide. One week washout period
was maintained between treatments. After this single dose interac-
tion study the same group was continued with the daily treatment
of interacting drug (atazanavir) for the next 8 days with regular
feeding. Later after 18 h fasting they were again given the com-
bined treatment on the 9th day.
Blood samples were withdrawn from the marginal ear vein of
each rabbit at 0, 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24 h. These blood
samples were analysed for blood glucose by GOD/POD method
using commercial glucose kits. Plasma insulin was measured by
Radio Immuno Assay method using a commercially available kit
(human insulin as standard; Insik-5, Sorin Biomedica, Saluggia,
Italy) as per the instructions provided by the manufacturers at 3
and 24 h. The serum gliclazide concentrations were determined
by HPLC method [18]. The pharmacokinetic parameters of glicla-
zide were determined on subjecting the concentration-time data
to non-compartmental analysis using WinNonlin (version 5.0.1)
software.2.6. Data and statistical analysis
Data were expressed as mean ± SEM. The signiﬁcance was
determined by applying Student’s paired ‘t’ test.3. Results
3.1. Pharmacodynamic interaction study in normal and diabetic rats
Gliclazide produced hypoglycemic activity with maximum bi-
phasic reduction of 40.88 ± 0.57% and 39.01 ± 0.73% in normal rats,
and 42.95 ± 1.74% and 44.14 ± 1.78% in diabetic rats at 2 h and 8 h,
respectively. Atazanavir has no signiﬁcant effect on the blood glu-
cose levels in normal and diabetic rats. In combination, atazanavir
produced enhanced hypoglycemic effect of gliclazide with maxi-
mum blood glucose reduction of 48.27 ± 1.04% & 45.69 ± 1.53%
and 50.14 ± 0.87% & 47.54 ± 1.00% at 2 h and 8 h, following single
dose and multiple dose administration of atazanavir, respectively,
in normal rats (Table 1). In combination, atazanavir produced en-
hanced hypoglycemic effect of gliclazide with maximum blood glu-
cose reduction of 44.99 ± 1.13% & 48.00 ± 1.26% and 48.89 ± 1.18%
& 50.25 ± 0.87% at 2 h and 8 h, following single dose and multiple
dose administration of atazanavir, respectively, in diabetic rats (Ta-
Table 1
Mean percent blood glucose reduction in normal and diabetic rats (N = 6).
Time (h) Normal rats Diabetic rats
G A A + G (SDT) A + G (MDT) G A A + G (SDT) A + G (MDT)
1 31.96 ± 0.60 06.30 ± 0.66 36.15 ± 1.42* 38.55 ± 1.88* 33.43 ± 1.89 06.55 ± 2.64 37.58 ± 1.40** 39.16 ± 1.18**
2 40.88 ± 0.57 04.90 ± 0.96 48.27 ± 1.04* 50.14 ± 0.87* 42.95 ± 1.74 04.82 ± 2.59 44.99 ± 1.13 48.89 ± 1.18**
3 28.62 ± 0.58 03.37 ± 0.80 35.00 ± 2.02* 36.71 ± 1.49* 30.89 ± 2.01 03.12 ± 2.71 36.86 ± 1.92** 37.78 ± 1.76**
4 23.40 ± 0.81 02.28 ± 1.02 28.82 ± 1.46* 33.04 ± 1.48* 24.81 ± 1.99 02.69 ± 2.41 30.07 ± 1.31** 32.74 ± 0.94**
6 30.10 ± 0.84 01.13 ± 0.51 38.01 ± 1.35* 42.68 ± 1.24* 36.76 ± 1.63 04.74 ± 1.87 40.07 ± 1.44** 42.59 ± 1.15**
8 39.01 ± 0.73 06.72 ± 0.68 45.69 ± 1.53* 47.54 ± 1.00* 44.14 ± 1.78 06.03 ± 2.22 48.00 ± 1.26** 50.25 ± 0.87**
10 26.76 ± 0.53 08.94 ± 0.72 32.85 ± 1.43* 35.25 ± 1.25* 28.77 ± 2.09 08.10 ± 1.37 31.75 ± 1.47** 32.54 ± 1.27**
12 13.74 ± 0.62 09.27 ± 0.71 25.15 ± 1.57* 28.21 ± 0.74* 24.63 ± 2.36 04.62 ± 1.76 26.17 ± 1.92 28.56 ± 1.77**
G: gliclazide – 2 mg/kg bd. wt. treated group.
A: atazanavir – 36 mg/kg bd. wt. treated group.
A + G (SDT): atazanavir + gliclazide (single dose treatment).
A + G (MDT): atazanavir + gliclazide (multiple dose treatment).
* Signiﬁcant at P < 0.05 compared to gliclazide control (normal rats).
** Signiﬁcant at P < 0.05 compared to gliclazide control (diabetic rats).
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Fig. 1. Effect of atazanavir/gliclazide and their combination on serum insulin levels
in normal rabbits (N = 6).
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ple dose treatment of atazanavir than single dose treatment.
3.2. Pharmacodynamic interaction study in normal rabbits
Gliclazide produced hypoglycemic activity with maximum
reduction of 35.22 ± 1.09% at 3 h in normal rabbits. Atazanavir
has no signiﬁcant effect on the blood glucose levels in normal rab-
bits. Atazanavir produced enhanced hypoglycemic effect of glicla-
zide with maximum reduction of 43.66 ± 0.39% and 45.72 ± 0.94%
in the blood glucose in normal rabbits at 3 h following single dose
and multiple dose treatment of atazanavir, respectively (Table 2).
The enhancement in gliclazide effect is more with the multiple
dose treatment of atazanavir than the single dose treatment. The
serum insulin levels were increased with atazanavir treatment in
normal rabbits (Fig. 1).
3.3. Pharmacokinetic interaction study in normal rabbits
The serum gliclazide levels were increased, and pharmacoki-
netic parameters of gliclazide like Cmax, Tmax, AUC, AUMC, Kel and
T1/2 were altered signiﬁcantly with single- and multiple-dose treat-
ments of atazanavir in normal rabbits (Table 3). The percent in-
crease of serum gliclazide level is 22.73% and 24.26% following
single dose and multiple dose administration of atazanavir,
respectively.
4. Discussion
Drug interactions are usually seen in clinical practice, and the
mechanisms of interactions are evaluated usually in animal models
(rodent and non-rodent). We studied the inﬂuence of atazanavir onTable 2
Mean percent blood glucose reduction in normal rabbits (N = 6).
Time (h) Gliclazide
(5.6 mg/1.5 kg bd. wt.)
Atazanavir
(28 mg/1.5 kg bd. wt.)
1 20.43 ± 1.80 06.56 ± 0.82
2 26.59 ± 0.66 05.30 ± 1.40
3 35.22 ± 1.09 04.59 ± 1.47
4 27.63 ± 1.76 04.57 ± 1.24
6 25.52 ± 0.75 03.17 ± 1.77
8 19.70 ± 2.44 08.47 ± 1.43
12 12.54 ± 1.54 06.38 ± 1.81
16 07.16 ± 4.01 04.95 ± 1.42
20 06.79 ± 1.34 04.93 ± 1.76
24 03.92 ± 1.41 03.18 ± 0.90
* Signiﬁcant at P < 0.05 compared to gliclazide control.the pharmacodynamics and pharmacokinetics of gliclazide in rats
(rodents) and rabbits (non-rodent). The normal rat model served
to quickly identify the interaction and the diabetic rat model
served to validate the same response in the actually used condition
of the drug. The rabbit model is another dissimilar species to vali-
date the occurrence of the interaction. The multiple dose effect of
atazanavir on gliclazide activity was also studied for the inﬂuence
of long term treatment with atazanavir, since both are used for
chronic period.
Rats are known to be more sensitive to gliclazide response. So
we have conducted the dose effect-relationship study of gliclazide
to select the oral dose, which produces approximately 35% of bloodAtazanavir + gliclazide
(single dose treatment)
Atazanavir + gliclazide
(multiple dose treatment)
28.87 ± 1.03* 30.48 ± 1.05*
34.15 ± 0.52* 36.87 ± 0.51*
43.66 ± 0.39* 45.72 ± 0.94*
35.90 ± 0.64* 37.55 ± 1.28*
34.85 ± 0.80* 36.53 ± 1.27*
28.87 ± 2.08* 30.82 ± 2.63*
20.74 ± 2.29* 24.04 ± 2.48*
16.90 ± 1.72* 20.17 ± 2.05*
12.32 ± 0.99* 15.92 ± 1.35*
10.20 ± 083* 12.75 ± 1.08*
Table 3
Mean pharmacokinetic parameters of gliclazide before and after atazanavir administration in rabbits.
Pharmacokinetic parameter Gliclazide Atazanavir + Gliclazide (single dose treatment) Atazanavir + Gliclazide (multiple dose treatment)
Cmax (ng/ml) 346.79 ± 4.21 428.21 ± 8.68* 431.63 ± 8.61*
Tmax (h) 3.00 ± 0.00 3.00 ± 0.00* 3.00 ± 0.00*
AUC0–24 (ng/ml/h) 4013.84 ± 147.00 4913.80 ± 112.05* 4969.46 ± 11.53*
AUC0–inf (ng/ml/h) 4777.04 ± 206.58 6048.95 ± 176.75* 6143.66 ± 174.7*
AUC% Extrapolation 15.82 ± 1.20 18.62 ± 1.51* 18.98 ± 1.45*
AUMC0–24 (ng/ml/h*h) 38787.60 ± 1809.59 46863.51 ± 1440.81* 47517.88 ± 1426.66*
AUMC0–inf (ng/ml/h*h) 66332.61 ± 4644.81 89966.53 ± 5680.50* 92221.81 ± 5612.05*
AUMC% Extrapolation 40.82 ± 2.54 47.07 ± 2.93* 47.71 ± 2.78*
MRT0–24 (h) 9.64 ± 0.13 9.53 ± 0.09 9.55 ± 0.09
MRT0–inf (h) 13.82 ± 0.49 14.81 ± 0.62* 14.95 ± 0.60*
Kel (h1) 0.08 ± 0.00 0.07 ± 0.00 0.07 ± 0.00
T1/2 (h) 8.15 ± 0.53 9.41 ± 0.58* 9.50 ± 0.56*
* Signiﬁcant at P < 0.05 compared to gliclazide control.
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rat model when administered alone, which may be due to its bili-
ary excretion and entero hepatic cycling. Such an effect is not seen
in the rabbit model. The enterohepatic recirculation observed in
our study was consistent with the previous reports in animal mod-
els [1,12] and humans [19]. As per the recent clinical study [19],
the extent of mean enterohepatic recirculation observed in hu-
mans was consistent with data from animals. This consistency will
address the probable correlation of preclinical studies to human
subjects.
In our study, atazanavir alone did not produce any signiﬁcant
activity on blood glucose levels of rats (normal and diabetic) and
rabbits, and our results were consistent with earlier reports from
in vitro [20] and in vivo studies [6,21]. This suggested that protease
inhibitors effects were drug speciﬁc but not class speciﬁc, as other
protease inhibitors have a signiﬁcant impact on glucose homeosta-
sis. Interestingly, however, the gliclazide hypoglycemic and antidi-
abetic activity was signiﬁcantly enhanced by atazanavir, following
a single and multiple dose treatment in rat and rabbit models, and
this conﬁrmed the presence of potential interaction between gli-
clazide and atazanavir. Further, the presence of interaction was
supported by an increase in serum insulin levels with atazanavir
treatment. It is clear that since atazanavir did not alter blood glu-
cose levels on its own, the increase in the effect of gliclazide on
blood glucose may be due to improved blood gliclazide level in
the presence of atazanavir, as it was conﬁrmed by pharmacokinetic
interaction study in rabbits.
There was a signiﬁcant rise in serum gliclazide levels and an
alteration in pharmacokinetic parameters like Cmax, Tmax, AUC,
AUMC, Kel and T1/2 of gliclazide with single- and multiple-dose
treatments of atazanavir. The increase in AUC and AUMC indicates
improved availability of gliclazide in presence of atazanavir. There
might not be interaction at absorption level, since oral absorption
of atazanavir is not high. Gliclazide is a highly protein bound drug
(85–99%) [22], whereas atazanavir is bound to proteins to the ex-
tent of 86–89% [23]. Hence, the possibility of displacing gliclazide
from protein bound sites by atazanavir was low. Moreover, the rise
of gliclazide blood levels in the presence of atazanavir might be
other than improved absorption and altered distribution.
The altered Kel and T1/2 indicates alteration either in metabolism
or the excretion process. Atazanavir is reported to be a potent
inhibitor of CYP3A4 and CYP2C9 [11], and there is more possibility
of atazanavir for inhibition of metabolism of gliclazide, which is
also metabolized by both CYP2C9 and CYP3A4 [10,12]. Further gli-
clazide is eliminated through renal (80%) and biliary (20%) routes
[22,24]. The major elimination pathway of atazanavir is the biliary
route. Atazanavir is eliminated by 13% being in urine and 79% in
feacal matter [23]. Hence, there is also a possibility for interaction
between atazanavir and gliclazide at biliary excretion. However,the drug atazanavir did not change the pattern of biphasic re-
sponse of gliclazide, indicating that it did not interfere with the
reabsorption of gliclazide in its enterohepatic circulation in rats.
Hence, the interaction at hepatic metabolism with reduced glicla-
zide metabolism by atazanavir, leading to raised serum levels, re-
mains possible.5. Conclusions
The interaction appears to be pharmacokinetic interaction at
metabolic level. Since the interaction was seen in two dissimilar
species, it is likely to occur in humans also leading to increased
activity of gliclazide, which may need dosage adjustment. Hence,
care should be taken when the combination is prescribed for clin-
ical beneﬁt in diabetic patients. However, the present study war-
rants further studies to ﬁnd out the relevance of this interaction
in human beings.Acknowledgements
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